Iressa

[gefitinib tablets]

Non- Small Cell Lung Cancer (NSCLC);

Studies of First-line Treatment in Combination with ChemotherapyÑ Two large trials were conducted in chemotherapy-naïve patients with stage III and IV non- small cell lung cancer. Two thousand one hundred thirty patients were randomized to receive IRESSA 250 mg daily, IRESSA 500 mg daily, or placebo in combination with platinum-based chemotherapy regimens. The chemotherapies given in these first-line trials were gemcitabine and cis- platinum (N= 1093) or carboplatin and paclitaxel (N= 1037). The addition of IRESSA did not demonstrate any increase, or trend toward such an increase, in tumor response rates, time to progression, or overall survival.

Page:  << Prev | 1 | 2 | 3 | 4 | 5